Method evidence record

Adaptive Phase IV study

An Adaptive Phase IV study is a post-marketing surveillance study conducted after a drug or intervention has received regulatory approval, augmented with pre-specified adaptive design elements that allow pre-planned modifications to the study protocol in response to accumulating data. These modifications may include sample size re-estimation, endpoint adjustments, or population enrichment, all governed by statistical rules set before the study begins, preserving scientific integrity while increasing efficiency.

Sources recorded, not reviewed

Source record

Citations copied verbatim from the method’s source record. No claim-level verification is inferred from them.

Adaptive Phase IV Post-Marketing Study

Taxonomic method record · process-pipeline / epidemiology

Chow, S. C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman and Hall/CRC. · ISBN 978-1584889625
U.S. Food and Drug Administration. (2019). Adaptive Designs for Clinical Trials of Drugs and Biologics: Guidance for Industry. FDA. · URL

Open full method

Curated claims

Claims persisted in the evidence ledger, each with its own assessment.

No curated claims yet

This view does not invent a claim assessment when the ledger has none.

Related methods

Generated from the method graph and shown as machine-suggested relations — no evidence claim is inferred.

Taxonomic bucketAdaptive Phase III clinical trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketAdaptive Randomized Clinical Trialmachine-suggested · Relational suggestion, not evidence.Taxonomic bucketBayesian Phase IV studymachine-suggested · Relational suggestion, not evidence.Taxonomic bucketCohort Studymachine-suggested · Relational suggestion, not evidence.Taxonomic bucketPhase IV studymachine-suggested · Relational suggestion, not evidence.Taxonomic bucketPragmatic phase IV studymachine-suggested · Relational suggestion, not evidence.